

Interactions Between Recreational Drugs and Antiretroviral Agents

Tony Antoniou and Alice Lin-in Tseng

OBJECTIVE: To summarize existing data regarding potential interactions between recreational drugs and drugs commonly used in the management of HIV-positive patients.

DATA SOURCES: Information was obtained via a MEDLINE search (1966–August 2002) using the MeSH headings human immunodeficiency virus, drug interactions, cytochrome P450, medication names commonly prescribed for the management of HIV and related opportunistic infections, and names of commonly used recreational drugs. Abstracts of national and international conferences, review articles, textbooks, and references of all articles were also reviewed.

STUDY SELECTION AND DATA EXTRACTION: Literature on pharmacokinetic interactions was considered for inclusion. Pertinent information was selected and summarized for discussion. In the absence of specific data, prediction of potential clinically significant interactions was based on pharmacokinetic and pharmacodynamic properties.

RESULTS: All protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors are substrates and potent inhibitors or inducers of the cytochrome P450 system. Many classes of recreational drugs, including benzodiazepines, amphetamines, and opioids, are also metabolized by the liver and can potentially interact with antiretrovirals. Controlled interaction studies are often not available, but clinically significant interactions have been observed in a number of case reports. Overdoses secondary to interactions between the “rave” drugs methylenedioxymethamphetamine (MDMA) or γ -hydroxybutyrate (GHB) and PIs have been reported. PIs, particularly ritonavir, may also inhibit metabolism of amphetamines, ketamine, lysergic acid diethylamide (LSD), and phencyclidine (PCP). Case series and pharmacokinetic studies suggest that nevirapine and efavirenz induce methadone metabolism, which may lead to symptoms of opiate withdrawal. A similar interaction may exist between methadone and the PIs ritonavir and nelfinavir, although the data are less consistent. Opiate metabolism can be inhibited or induced by concomitant PIs, and patients should be monitored for signs of toxicity and/or loss of analgesia. PIs should not be coadministered with midazolam and triazolam, since prolonged sedation may occur.

CONCLUSIONS: Interactions between agents commonly prescribed for patients with HIV and recreational drugs can occur, and may be associated with serious clinical consequences. Clinicians should encourage open dialog with their patients on this topic, to avoid compromising antiretroviral efficacy and increasing the risk of drug toxicity.

KEY WORDS: cytochrome P450, drug interactions, nonnucleoside reverse transcriptase inhibitors, protease inhibitors, recreational drugs, street drugs.

Ann Pharmacother 2002;36:1598-613.

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT

ACPE UNIVERSAL PROGRAM NUMBER: 407-00-02-033-H02

The advent of potent new therapies for HIV has seemingly turned the tide in the battle against this disease. Specifically, combinations of antiretroviral drugs that include a member of the protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) family offer new hope that the progression of the disease and death can

be delayed.¹⁻³ However, the addition of combination therapies to already complex medication regimens dramatically increases the likelihood of drug interactions.⁴⁻⁷ PIs and NNRTIs, in particular, have a propensity for causing drug interactions as a result of their ability to either inhibit or induce the cytochrome P450 (CYP450) enzyme system.⁸⁻¹³ The effects of medications commonly used by patients with HIV/AIDS on the body's various drug-metabolizing pathways are summarized in Table 1.⁸⁻¹³

Author information provided at the end of the text.

While numerous interactions of varying clinical significance have been well described¹⁰⁻¹² with these antiretrovirals, less is known about the potential for drug interactions with recreational drugs. This is an issue of concern, since drug use by injection remains a significant risk factor for the acquisition of HIV infection.^{14,15} According to the Centers for Disease Control and Prevention,¹⁶ the proportion of AIDS cases in the US associated with injection drug use has increased from 12% in 1981 to 25% of all new cases through June 2001. In Canada, the proportion of new HIV infections attributable to injection drug use increased from 24% in 1987–1990 to 34% in 1999.¹⁷

A report¹⁸ of a suspected fatal interaction between ritonavir and 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) has sparked demands for increased awareness and research in this area. Realistically, however, it is unlikely that pharmacokinetic interactions between drugs used in HIV pharmacotherapy and most recreational agents will be formally studied, due to legal and ethical constraints. However, it is often possible to predict potential interactions using *in vitro* and *in vivo* drug metabolism data.¹⁹ Since many recreational drugs are metabolized to some degree by the CYP450 system, it is reasonable to anticipate that concomitant use with PIs and delavirdine could possibly result in drug accumulation and/or toxicity. Similarly, treatment with enzyme inducers such as the NNRTI nevirapine may precipitate withdrawal reactions to recreational agents metabolized by the CYP450 system. Interactions between the NNRTI efavirenz and recreational drugs may be more difficult to predict, given that efavirenz can both inhibit (3A4, 2C9/19) and induce (3A4) selected isoenzymes of the CYP450 system, although induction of CYP3A4 appears to predominate over inhibition of this particular isoenzyme.^{7,13}

The purpose of this review is to summarize data on drug interactions between recreational drugs and antiretrovirals. In the absence of such data, the potential for an interaction is addressed based on the metabolic fate of the recreational drug. General information regarding the steps involved in drug metabolism has been reviewed elsewhere.¹⁹

Methods

Information was collected on documented or suspected interactions and metabolic pathways of both commonly prescribed HIV medications and commonly used recreational drugs. Information was retrieved via a MEDLINE search (1966–August 2002) using the MeSH headings human immunodeficiency virus, drug interactions, cytochrome P450, names of antiretrovirals, and chemical and common names of frequently used recreational drugs including methylenedioxymethamphetamine (MDMA), methamphetamine, γ -hydroxybutyrate (GHB), ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), cocaine, heroin, methadone, meperidine, codeine, morphine, oxycodone, benzodiazepines, marijuana, and alcohol. Abstracts of international and national conferences, review articles, textbooks, and references of all articles were also searched. All literature on pharmacokinetic or pharmacodynamic interactions was considered for inclusion. When data on a particular combination were unavailable, a possible or potential interaction was predicted based on the metabolic fate of the involved agents.

Results

Many prescription, nonprescription, and recreational drugs undergo extensive hepatic metabolism via CYP450 isoenzymes and/or glucuronidation. Thus, there is potential for significant interactions between these agents and antiretrovirals, particularly PIs and NNRTIs. Concentrations of many recreational drugs may be significantly increased or decreased in the presence of these antiretrovirals and may be associated with serious adverse outcomes.

Rave Drugs

AMPHETAMINES

MDMA, also known as ecstasy, XTC, Adam, and Essence, is a commonly used substance at all-night dance parties known as raves and is also increasingly being used recreationally by young professionals. When MDMA is taken orally as a capsule or tablet at average doses of 75–100 mg,²⁰ users cite enhanced feelings of empathy for others, anxiolysis, and strong feelings of euphoria. MDMA is an amphetamine-like compound that undergoes demethylation principally by CYP2D6.²¹⁻²³ Concomitant administration with CYP2D6 inhibitors could lead to significant increases in MDMA exposure with potentially dangerous and even fatal consequences, as illustrated by a case report.¹⁸ Within a few hours of taking 180 mg of MDMA, a 32-year-old man with AIDS experienced symptoms suggestive of a heightened serotonergic state including tachypnea, tachycardia, cyanosis, and profuse sweating. He then experienced an apparent tonic-clonic seizure, tachypnea, and tachycardia (carotid pulse ~ 200 beats/min), and subsequently died from cardiorespiratory arrest. This patient had previously taken similar amounts of MDMA on several occasions without adverse effects,

Table 1. Metabolic Characteristics of Antiretrovirals⁸⁻¹³

Class	Enzyme Inhibitors	Enzyme Inducers
NNRTI	delavirdine	nevirapine
	CYP3A4	CYP3A4
	efavirenz	efavirenz
	CYP2B6, 3A4, 2C9/19	CYP3A4
PI	all inhibit CYP3A4	ritonavir
	ritonavir (in descending order of potency of inhibition)	GCT
	3A4>2D6>2C9>2C19>>2A6>2E1	CYP1A2
		CYP3A4 (possible)
		nelfinavir
	CYP2B6	GCT
	amprenavir	
	CYP2C19	
	nelfinavir	
	CYP2B6	

GCT = glucuronyltransferase; NNRTI = nonnucleoside reverse transcriptase inhibitor; PI = protease inhibitor.

but this was the first time he had taken MDMA since adding ritonavir 600 mg twice daily to his antiretroviral regimen. At autopsy, the patient's blood concentrations of MDMA were approximately tenfold higher than expected given the amount ingested. Since ritonavir is a well-known potent inhibitor of many hepatic isoenzymes including CYP2D6, the clinicians concluded that the patient likely experienced a fatal serotonergic reaction to MDMA as a result of an interaction with ritonavir.

The danger associated with this interaction may be magnified due to the large variability in the actual amount of MDMA between tablets and the presence of other chemicals (e.g., amphetamines, ephedrine) in some MDMA tablets whose metabolism can also be inhibited by ritonavir, leading to a life-threatening consequence.²⁴ Thus, the combination of MDMA and ritonavir should be avoided. Other isoforms of the CYP450 system may also be involved in the metabolism of MDMA, notably 1A2, 2B6, and 3A4.²³ All PIs can inhibit CYP3A4 activity to varying degrees, and ritonavir, nelfinavir, and the NNRTI efavirenz also demonstrate inhibitory activity against 2B6²⁵; therefore, individuals using MDMA should be warned about the potential for an interaction with these agents and advised to take appropriate precautions (e.g., use ~25% of the usual amount of MDMA, take breaks from dancing, ensure rave or party has medical team on site, maintain adequate hydration by avoiding alcohol and replenishing fluids regularly).

Other amphetamines, particularly methamphetamine (crystal meth, speed), may be used at raves. These drugs are also mainly metabolized by CYP2D6.²⁶⁻²⁸ Thus, potentially dangerous interactions with ritonavir may occur, and the combination should be avoided if possible.

GHB

GHB, also known as liquid ecstasy, grievous bodily harm, or G, is a naturally occurring metabolite of the neurotransmitter γ -aminobutyric acid (GABA) that is used at raves for its euphoric effects. Colorless, odorless, and tasteless, GHB has also been used in the context of date rape when slipped into beverages. The pharmacokinetics of GHB have not been well characterized. The major route of elimination is expired breath as carbon dioxide, although animal data^{29,30} suggest that first-pass metabolism may also play a large role in GHB clearance. Since first-pass metabolism is often mediated by the CYP450 system, it is possible that inhibitors of this system could predispose patients to GHB-related toxicity. As the precise metabolic pathway involved in the metabolism of GHB is unknown, patients who use this substance should be warned about the potential dangers of a drug interaction with PIs (especially ritonavir) and the NNRTIs delavirdine and, possibly, efavirenz.

The potential for an interaction is highlighted by a report³¹ of an HIV-positive patient taking ritonavir and saquinavir who developed symptoms consistent with GHB toxicity shortly after ingesting a small amount of GHB (~10 mg/kg). The patient had taken GHB to counter the

agitating effects of 2 MDMA tablets, which had lasted much longer (29 h) than when he had used MDMA prior to initiating antiretroviral therapy. Since the man had taken similar doses of both MDMA and GHB without incident prior to initiating therapy with ritonavir and saquinavir, the authors concluded that PI-mediated inhibition of MDMA and GHB was responsible for the adverse reactions.

KETAMINE

Ketamine, also known as special K or kit kat, may be used at raves for its dissociative, intoxicating, and amnesic properties. Users may inhale the powder form, while ketamine liquid is usually added to drinks and ingested orally. The main route of ketamine metabolism is *N*-demethylation to norketamine, a metabolite with approximately one-third the anesthetic activity of its parent compound. Norketamine is then hydroxylated and conjugated to water-soluble conjugates that are excreted in the urine.³² CYP2B6 appears to be the main enzyme involved in ketamine metabolism, with 3A4 and 2C9 involved to a lesser extent.³³ There are no studies or case reports describing interactions between ketamine and antiretroviral agents. However, since ritonavir, nelfinavir, and efavirenz are potent inhibitors of CYP2B6, patients who use ketamine recreationally may be at risk for ketamine toxicity due to drug accumulation. Animal studies^{34,35} suggest that ketamine may be a weak inhibitor of CYP3A4, although the clinical significance of this is unclear in the absence of human data. Still, until such results can be confirmed, it may be prudent to avoid recreational ketamine use while taking drugs that are CYP3A4 substrates and have narrow safety thresholds (e.g., cisapride, terfenadine, astemizole).

PCP

PCP, known on the street as angel dust, rocket fuel, or killer weed, may be used at raves for its hallucinogenic or dissociative properties. Users may also report feelings of empowerment and invulnerability with PCP use. PCP is metabolized in the liver through oxidative hydroxylation, with up to 5 metabolites being formed. CYP3A4 appears to play a major role in the hydroxylation of PCP.³⁶ Results from rat model studies also suggest that CYP2C11 may be involved in PCP metabolism³⁷ and that CYP2B1 may be inhibited *in vitro*.³⁸ Thus, it would be expected that concurrent use of PCP with PIs, delavirdine, and possibly efavirenz may result in elevated PCP concentrations and resultant toxicity. Patients using PCP who are also receiving treatment with antiretrovirals should be cautioned to use less than what they would normally use given the potential for a drug interaction.

LSD

LSD is also known popularly as acid or blotters, since it may be used in the form of paper microdots for its hallucinogenic and mild euphoric properties. Although the

CYP450 system may be involved in the metabolism of LSD, the exact contribution of this system in overall LSD clearance and the isoenzymes involved have not been detailed.^{39,40} Thus, anticipating drug interactions with LSD is extremely difficult. Patients who use LSD recreationally and who receive treatment with antiretrovirals should be cautioned about the possibility of an interaction and to be familiar with signs of LSD toxicity, and perhaps consider using a smaller amount than normal. Table 2^{18,21-23,26-40} summarizes the interactions between rave drugs and antiretrovirals.

Methadone

Since methadone is metabolized primarily by CYP3A4, with additional contributions by 2D6, 2C19, and 2B6, the likelihood of interactions with NNRTIs and PIs is high.⁴¹⁻⁴⁴ Several such interactions have been described in the literature and are summarized in Table 3.⁴⁵⁻⁷²

As expected, patients maintained on methadone who are subsequently treated with either efavirenz or nevirapine are at risk of developing opiate withdrawal symptoms due to NNRTI-mediated enzyme induction. Such patients may require an increase in their methadone dose, although the magnitude of the dose increase may not always parallel the reduction in total methadone exposure. For example, data reported by Clarke et al.⁴⁵ suggest that, despite a decrease of >50% in methadone AUC seen with the addition of

efavirenz, a mean increase in methadone dose of only 22% (in 10-mg increments) was required to counteract symptoms consistent with opiate withdrawal. A similar interaction has been described⁶⁸ between nevirapine and methadone, in that a mean increase in methadone dose of 16% was required to compensate for a 50% reduction in methadone AUC.

Interactions between PIs and methadone have been even less predictable. In vitro, the AUC for methadone increased twofold when the drug was administered with ritonavir and 30% when administered with indinavir.⁷³ A later study⁷⁴ in healthy volunteers did not confirm these findings, noting a decrease in the AUC of methadone of 36% with concomitant ritonavir. However, these results are somewhat limited since only a single 5-mg dose of methadone was studied. Similarly, reduced methadone concentrations have been noted in the presence of lopinavir/ritonavir⁷⁰ and nelfinavir.⁵³ These observations suggest that ritonavir, nelfinavir, and possibly lopinavir may be inducing an alternative route of methadone metabolism.^{52,57,58}

Reduced methadone concentrations have not always been accompanied by symptoms of opiate withdrawal. This lack of correlation between concentrations and clinical withdrawal may be related to a disproportionately larger induction in the metabolism of methadone's inactive *S*(+)-enantiomer as opposed to the *R*(-)-enantiomer, which harbors essentially all opiate activity.⁵⁴ Further studies need

Table 2. Interactions Between Antiretrovirals and Rave Drugs^{18,21-23,26-40}

Drug	Metabolism	Actual/Theoretical Interaction	Potential Significance	Recommendation
Amphetamines	CYP2D6 ²⁶⁻²⁸	possible ↑ concentrations with ritonavir	hypertension, hyperthermia, seizures, arrhythmias, tachycardia, tachypnea	avoid combination with ritonavir if possible; alternatively, start with 1/4–1/2 of initial amount of amphetamine used
GHB	expired breath as CO ₂ ; first-pass metabolism ^{29,30}	possible ↑ concentrations/prolonged effect with antiretrovirals, especially ritonavir	1 case ³¹ of GHB toxicity with ritonavir/saquinavir; myoclonic or seizure activity, bradycardia, respiratory depression, loss of consciousness	use cautiously with CYP450 inhibitors (i.e., PIs, delavirdine, efavirenz); become aware of signs/symptoms of GHB toxicity
Ketamine	CYP2B6 (main), 3A, 2C9 (both to lesser extent) ³²⁻³⁵	possible ↑ concentrations with antiretrovirals, especially, ritonavir, nelfinavir, and efavirenz	respiratory depression, loss of consciousness, hallucinations	use cautiously with CYP450 inhibitors, especially ritonavir, nelfinavir, and efavirenz; become aware of signs/symptoms of ketamine toxicity
LSD	unknown ^{39,40}	possible ↑ LSD concentrations	hallucinations, agitation, psychosis, flashbacks	use cautiously with CYP450 inhibitors (i.e., PIs, delavirdine, efavirenz); become aware of signs/symptoms of LSD toxicity
MDMA, Ecstasy	CYP2D6 ²¹⁻²³ (main), 1A2, 2B6, 3A4 (to lesser extent) ²³	possible ↑ concentrations with ritonavir, other PIs, efavirenz	1 death reported ¹⁸ ; hyponatremia, hyperthermia, arrhythmias, tremor, hyperreflexia, sweating, seizures, tachycardia, rhabdomyolysis	avoid combining with ritonavir if possible; alternatively use ~1/4–1/2 of usual amount and watch for signs of MDMA toxicity; stay well hydrated at party, avoid alcohol, take breaks from dancing
PCP	CYP3A, ³⁶ CYP2C11, ³⁷ inhibits CYP2B1 ³⁸	possible ↑ concentrations with antiretrovirals	seizures, hypertension, rhabdomyolysis, hyperthermia	use cautiously with CYP450 inhibitors (i.e., PIs, delavirdine, efavirenz); become aware of signs/symptoms of PCP toxicity

GHB = γ -hydroxybutyrate; LSD = lysergic acid diethylamide; MDMA = methylenedioxymethamphetamine; PCP = phencyclidine; PI = protease inhibitor.

Table 3. Interactions Between Antiretrovirals and Methadone⁴⁵⁻⁷²

Antiretroviral	Study Type	Patients	Interaction	Recommendation
NRTIs				
abacavir ⁶²	pharmacokinetic	19 pts. titrated to constant methadone dose (≥ 40 mg/d) over 14 d; days 15–28, received concomitant methadone and abacavir	slight \uparrow in methadone clearance by abacavir; no statistically significant change in C_{\max} , half-life, or renal clearance of methadone; methadone causes slight delay in rate but not extent of abacavir absorption	combination appears safe
didanosine/ stavudine ⁵⁹	pharmacokinetic	17 pts. on methadone maintenance and 10 control pts.; 2 pharmacokinetic studies completed for each subject and control (1 each for both drugs)	stavudine AUC 23%; didanosine AUC \downarrow 57%; effect primarily related to reduced bioavailability	no data to guide dose adjustments; monitor for virologic failure
didanosine EC capsule ⁷²	pharmacokinetic	HIV-negative patients (n = 17) on stable methadone dose; randomized to EC or tablet formulation, and crossed-over to alternative regimen after pharmacokinetic monitoring over 24 h; comparisons made to historical data in nonmethadone pts.	EC formulation provided didanosine plasma AUC concentrations comparable to historical controls in nonmethadone patients	combination of EC capsule of didanosine appears safe
zidovudine ⁶⁰	pharmacokinetic	14 HIV-positive pts. on methadone maintenance for at least 6 mo and 5 control pts.; all pts. were receiving zidovudine 200 mg po q4h	zidovudine AUC \uparrow 43% vs. control; no effect on methadone maintenance	monitor for zidovudine-related toxicities (e.g., nausea, vomiting, bone marrow suppression)
zidovudine ⁶¹	pharmacokinetic within subject	8 pts. started on acute methadone therapy as inpatients; both po and iv zidovudine pharmacokinetics determined before starting methadone, following acute methadone treatment, and after 2 mo of daily methadone	zidovudine AUC \uparrow 41% during acute methadone treatment and 29% during chronic treatment	
NNRTIs				
delavirdine ⁶³	pharmacokinetic	16 HIV-negative volunteers maintained on methadone and 15 controls, each treated with delavirdine 600 mg bid for 5 d	methadone did not alter pharmacokinetics of delavirdine or <i>N</i> -delavirdine; effect of delavirdine on methadone not studied	since delavirdine inhibits 3A4, monitor for symptoms of opiate toxicity (e.g., miosis, drowsiness, \downarrow rate and depth of respiration, nausea, vomiting, constipation, bradycardia, hypotension) until further data available
efavirenz ⁴⁵	pharmacokinetic	11 pts. on stable methadone maintenance, due to begin antiretroviral therapy with 2 NRTIs and efavirenz	efavirenz \downarrow methadone C_{\max} ($p = 0.007$) and AUC by mean of 60%; pts. developed symptoms of methadone withdrawal 8–10 d after starting efavirenz and received \uparrow methadone dose (10-mg increments) until symptoms resolved (22% mean \uparrow in methadone dose required)	monitor for symptoms of opiate withdrawal (e.g., lacrimation, rhinorrhea, diaphoresis, restlessness, insomnia, dilated pupils, piloerection); adjust methadone dose if necessary
efavirenz ⁴⁷	case report	1 pt. on methadone 100 mg/d for >1 y; switched from nelfinavir/lamivudine/stavudine to efavirenz-containing regimen	4 wk after introduction of efavirenz, pt. reported tiredness, headache, cold sweats, shivering; concentrations of (<i>R</i>)-methadone (active enantiomer of methadone) before and after introduction of efavirenz were 168 and 90 ng/mL, respectively; methadone dose \uparrow to 180 mg/d before symptoms disappeared	

C_{\max} = maximum plasma concentration; C_{\min} = minimum plasma concentration; EC = enteric coating; EC_{50} = 50% effective concentration; HAART = highly active antiretroviral therapy; HCV = hepatitis C virus; HGC = hard-gel capsule; NNRTI = nonnucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; SGC = soft-gel capsule.

(continued on page 1603).

Table 3. Interactions Between Antiretrovirals and Methadone⁴⁵⁻⁷² (continued)

Antiretroviral	Study Type	Patients	Interaction	Recommendation
efavirenz ⁶⁴	case report	3 HIV-infected iv drug users on methadone	opiate withdrawal symptoms emerged 4–7 d following introduction of efavirenz; methadone concentrations in 1 pt. were 65% lower with efavirenz than at baseline; pts. required 66–133% ↑ in methadone dose	
nevirapine, then efavirenz ⁴⁸	case report	pt. stabilized on methadone 40 mg/d; antiretroviral therapy changed from zidovudine/lamivudine to stavudine/didanosine/nevirapine and, later, efavirenz	2 d following change, pt. experienced symptoms compatible with opiate withdrawal (e.g., cramps, tremor, rhinorrhea); symptoms stopped with discontinuation of nevirapine and recurred with nevirapine rechallenge; symptoms recurred following change to efavirenz in spite of dose ↑ to 80 mg/d; methadone concentrations stable despite dose increase	
nevirapine ⁴⁶	case report	1 pt. on methadone 80 mg/d for 3 y; switched from stavudine/didanosine/saquinavir-HGC nelfinavir after 1 mo (because of didanosine intolerance) to stavudine/nelfinavir/saquinavir-SGC/nevirapine	1 wk following the change to a nevirapine-containing regimen, the pt. experienced symptoms of methadone withdrawal (e.g., total body pain, nausea, vomiting, insomnia, sweats, sense of impending doom); the dose ↑ over 4 wk to 130 mg/d and symptoms resolved	monitor for symptoms of opiate withdrawal (see Efavirenz); adjust methadone dose if necessary
nevirapine ⁵⁰	retrospective chart review	7 pts. on chronic methadone maintenance following initiation of treatment with nevirapine-containing regimens	methadone withdrawal precipitated in all pts. within 4–8 d of initiating nevirapine; methadone concentrations subtherapeutic in 3 pts.; dose ↑ necessary; 4 pts. discontinued nevirapine therapy	
nevirapine ⁵¹	case series	5 pts. in methadone maintenance program starting nevirapine-based HAART	4 pts. exhibited symptoms of opiate withdrawal 6–15 d after beginning nevirapine therapy; 2 pts. discontinued nevirapine; 2 pts. remained on therapy but required ↑ methadone dose (33% and 100%)	
nevirapine ⁴⁹	prospective	45 iv drug users stabilized on methadone and treated with nevirapine, didanosine, and lamivudine, all once daily	30% of the pts. required ↑ methadone dose due to withdrawal symptoms	
nevirapine ⁶⁸	pharmacokinetic	8 pts. on stable daily doses of methadone beginning treatment with nevirapine-based HAART	nevirapine ↓ methadone AUC by a mean of 50%; 6 pts. reported symptoms of methadone withdrawal 8–10 d after starting nevirapine; methadone dose ↑ in increments of 10 mg (mean ↑ 16%)	
PIs				
amprenavir ⁵⁵	pharmacokinetic	16 opiate-dependent, HIV-negative pts. on at least 30 d of stable methadone doses; methadone concentrations reassessed after 10 d of amprenavir 1200 mg bid	preliminary data for 12 subjects: AUC of R-methadone ↓ 12%, AUC of S-methadone ↓ 24%; no change in opiate pharmacodynamics	combination appears safe based on preliminary data
indinavir ⁶⁹	pharmacokinetic	12 HIV-positive pts. on methadone 20–60 mg/d; indinavir 800 mg po q8h added	no significant effect of indinavir on methadone AUC vs. historical controls; no significant effect of methadone on indinavir AUC, but ↑ indinavir C _{min} 50–100% and ↓ indinavir C _{max} 16–36%, all vs. historical controls	combination appears safe
indinavir, nelfinavir, ritonavir, saquinavir ⁵⁸	case series	methadone concentrations measured prior to and at least 1 wk after addition of a PI to stable dual NRTI therapy in 10 pts. in methadone maintenance program	methadone concentrations unchanged in 6 pts. switched to indinavir and 1 pt. switched to saquinavir; methadone steady-state concentrations ↓ 40–50% in 1 pt. switched to ritonavir and 2 pts. switched to nelfinavir	monitor for symptoms of opiate withdrawal (see Efavirenz) with nelfinavir and ritonavir; adjust methadone dose if necessary

C_{max} = maximum plasma concentration; C_{min} = minimum plasma concentration; EC = enteric coating; EC₅₀ = 50% effective concentration; HAART = highly active antiretroviral therapy; HCV = hepatitis C virus; HGC = hard-gel capsule; NNRTI = nonnucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; SGC = soft-gel capsule.

(continued on page 1604)

Table 3. Interactions Between Antiretrovirals and Methadone⁴⁵⁻⁷² (continued)

Antiretroviral	Study Type	Patients	Interaction	Recommendation
lopinavir/ ritonavir ⁷⁰	prospective pharmacokinetic	8 HIV/HCV coinfectd pts. on methadone maintenance; methadone concentrations measured prior to and following 14 d of lopinavir/ritonavir in combination with 2 NRTIs	lopinavir/ritonavir ↓ methadone AUC 36% and ↓ methadone C _{max} 44%; no pt. exhibited symptoms of methadone withdrawal during the study or the 6-wk follow-up	combination appears safe; monitor for symptoms of opiate withdrawal (see Efavirenz) and adjust methadone dose if necessary
nelfinavir ⁵³	prospective pharmacokinetic	14 pts. stabilized on a fixed methadone dose for at least 1 mo before nelfinavir 1250 mg po bid for 8 d was added	concentrations of <i>S</i> (+)-methadone and <i>R</i> (-)-methadone ↓ by 47% and 39%, respectively; no pt. exhibited withdrawal symptoms; no dosage adjustments were necessary	monitor for symptoms of opiate withdrawal (see Efavirenz); adjust methadone dose if necessary
nelfinavir ⁵⁶	retrospective case series	75 pts. on stable methadone dose started on nelfinavir	2 of 75 pts. needed slight ↑ in methadone dose (10 mg/d); otherwise, no impact of nelfinavir on methadone activity	
nelfinavir ⁵⁷	case report	1 pt. on stable methadone dose of 100 mg/d, indinavir and zalcitabine; stavudine and nelfinavir added to regimen	within 6 wk of medication change, pt. developed opiate withdrawal symptoms, which ↑ in severity over 3 mo; methadone dose ↑ at 1 to 2-wk intervals; subtherapeutic methadone concentrations documented until dose of 285 mg/d attained	
nelfinavir ⁶⁵	pharmacokinetic	16 HIV-negative volunteers on stable methadone dose for 4 wk and 13 controls received nelfinavir 1250 mg po bid for 5 d	nonsignificant ↑ in median nelfinavir 12-h trough concentration with methadone; 12-h AUC of M8 53% lower than control	
nelfinavir ⁶⁶	multisite, retrospective	32 pts. on stable methadone dose receiving nelfinavir-based HAART; 84% of pts. coinfectd with HCV	17% of pts. required methadone dose adjustments (mean 26 mg); otherwise, well-tolerated combination	
ritonavir/ saquinavir ⁵²	case report	1 pt. on methadone 90 mg/d for 2 y; antiretrovirals changed from indinavir/lamivudine/zidovudine to ritonavir/saquinavir/stavudine because of virologic progression	1 wk following initiation of ritonavir-containing regimen, pt. was admitted to hospital with shakiness, diaphoresis, blurred vision, anxiety, and hypotension; methadone plasma concentration on admission was 210 ng/mL (within therapeutic range; however, no concentrations prior to initiation of ritonavir); methadone dose gradually ↑ to 130 mg/d	monitor for symptoms of opiate withdrawal (see Efavirenz); adjust methadone dose if necessary
ritonavir/ saquinavir ⁶⁷	pharmacokinetic	12 HIV-negative volunteers on stable methadone dose evaluated before and after 14 d of once-daily saquinavir/ritonavir (1600 mg/100 mg)	clinically insignificant change in unbound methadone concentrations; 83% of subjects had C _{min} of saquinavir >EC ₅₀	
ritonavir/ saquinavir ⁵⁴	24-h study before and after 15 d of antiretroviral therapy to exam- ine effect of ritonavir/saquin- avir on methadone kinetics	12 pts. receiving stable methadone dose for at least 2 wk	↓ <i>S</i> -methadone AUC 40% and ↓ <i>R</i> -methadone AUC 32%; however, when change in methadone AUC expressed in terms of unbound methadone, change in AUC no longer significant; no evidence of opiate withdrawal	
ritonavir/ saquinavir ⁷¹	retrospective	18 HIV-positive pts. beginning once-daily therapy with ritonavir 100 mg, and saquinavir-SGC 1600 mg and 5 HIV-positive pts. beginning once-daily therapy with ritonavir 200 mg and indinavir 1200 mg; all pts. on methadone, 19 pts. coinfectd with HCV	no pt. required methadone dose adjustment	

C_{max} = maximum plasma concentration; C_{min} = minimum plasma concentration; EC = enteric coating; EC₅₀ = 50% effective concentration; HAART = highly active antiretroviral therapy; HCV = hepatitis C virus; HGC = hard-gel capsule; NNRTI = nonnucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; SGC = soft-gel capsule.

to be conducted comparing methadone with PIs to better clarify the nature of these interactions. Clinicians should be prepared for the possibility that some patients stabilized on methadone might require a dose increase when nelfinavir or ritonavir is introduced.

Interactions between methadone and the nucleoside reverse transcriptase inhibitors zidovudine, didanosine, and stavudine have also been described.^{59–61} Overall, methadone appears to increase total exposure to zidovudine. The mechanisms underlying this interaction appear to involve inhibition of zidovudine glucuronidation and, to a lesser extent, decreased renal clearance of zidovudine. Although the clinical implications of these findings are unclear, patients receiving the combination of methadone and zidovudine should be monitored for zidovudine-related toxicities such as nausea, vomiting, headaches, and myelosuppression.^{60,61} Since many of these symptoms may mirror those of opiate withdrawal, patients may confuse the symptoms of zidovudine toxicity with a requirement for a higher methadone dose. However, methadone concentrations do not appear to be altered by concomitant zidovudine administration, thereby discounting the association of such symptoms with opiate withdrawal.

In contrast to zidovudine, methadone appears to decrease concentrations of both stavudine and didanosine (buffered tablet formulation), possibly by delaying absorption of these agents and thereby allowing enhanced time for enzymatic or acid-catalyzed degradation. Since didanosine is more prone to acid-catalyzed degradation than is stavudine, the impact of methadone on didanosine concentrations is more pronounced than for stavudine.⁵⁹ This theory is corroborated by recent evidence⁷² which indicates that the impact of methadone on didanosine concentrations is negligible when didanosine is administered as an enteric-coated capsule preparation, as such a coating would be expected to protect the drug from degradation until it has cleared the stomach. As well, the significance of reductions in didanosine concentrations is unclear, since intracellular concentrations of dideoxyadenosine triphosphate were not measured, and neither virologic nor immunologic outcomes were addressed. Although an increase in the dose of didanosine may be necessary when the buffered tablet formulation is taken with methadone, there are currently no guidelines for dosage adjustment.

As well as being a substrate of the CYP450 system, methadone can also act as an inhibitor of the 2D6 and 3A isoforms.^{75–77} It is therefore possible that concomitant use of methadone and PIs or NNRTIs may result in increased antiretroviral concentrations and predispose patients to drug-specific adverse events. However, methadone did not alter the pharmacokinetics of delavirdine, a CYP3A4 substrate.⁶³ In addition, aside from a reduction in concentrations of the pharmacologically active M8 metabolite, significant changes to the pharmacokinetics of nelfinavir were not observed with concomitant administration of methadone.⁶⁵ The metabolism of nelfinavir to its M8 metabolite is mediated by CYP2C19, suggesting that methadone may inhibit this isoenzyme as well. Although viro-

logically active, a reduction in M8 concentrations does not appear to be clinically significant.⁷⁸ Thus, significant elevations in the concentrations of PIs and NNRTIs may not occur with methadone. Still, the impact of methadone on other members of these classes is unknown and, as with zidovudine, it may be difficult to discriminate between symptoms associated with PI toxicity (e.g., nausea, vomiting, diarrhea) and methadone withdrawal. However, since enzyme inhibition is an acute process, while enzyme induction occurs following several days of drug administration, it may be possible to distinguish the 2 interactions based on the time course of symptom development. Specifically, symptoms that develop within 2–3 days of concomitant administration may be due to PI toxicity, whereas those that develop after 6 days are more likely to be related to opiate withdrawal.

Meperidine and Other Opiates

Two pathways are involved in meperidine metabolism: hydrolysis to meperidinic acid by liver carboxylesterases and demethylation to normeperidine by microsomal enzymes. Demethylation to normeperidine may be mediated by the CYP450 system, although the exact isoenzyme involved is unknown.^{79,80} In patients with renal failure or with frequent dosing, normeperidine can accumulate, leading to central nervous system (CNS) excitatory toxicity.

In an open-label study,⁸¹ 8 HIV-negative volunteers received meperidine 50 mg prior to treatment and following 10 days of treatment with escalating doses of ritonavir. Meperidine AUC decreased 67% in the presence of ritonavir ($p < 0.005$), while normeperidine AUC increased 47%, suggesting that ritonavir induces the metabolism of meperidine to normeperidine. However, since normeperidine has some pharmacologic activity, the potential for decreased analgesic effect and risk of opiate withdrawal may be lessened. On the other hand, because normeperidine possesses CNS excitatory effects, patients who use meperidine and ritonavir concomitantly may be at increased risk for seizures. Patients with renal failure may also be at increased risk for CNS excitatory toxicity due to normeperidine accumulation.

Reports detailing interactions between antiretrovirals and commonly used opiate analgesics such as codeine, morphine, or oxycodone are lacking. Postulated interactions between these opiates and antiretrovirals are described in Table 4.^{79–91}

Cocaine and Heroin

The significant role played by cocaine in the transmission of HIV cannot be underestimated. While injecting cocaine or heroin puts users at risk of acquiring HIV through contaminated syringes, smoking “crack” cocaine may independently be associated with acquisition of HIV infection through its association with high-risk sexual practices such as the exchange of drugs for sex.^{92–94} Since patients who acquire HIV in the context of crack or cocaine use may con-

continue their drug use practices, an understanding of the potential for interactions with antiretrovirals is important.

Cocaine is metabolized chiefly by 1 of 3 pathways.⁹⁵ Spontaneous hydrolysis of cocaine to benzoylecgonine accounts for approximately 39%, 30%, and 16% of a single dose of cocaine administered by the intravenous, intranasal, and smoked routes, respectively.⁹⁶ Degradation by serum and hepatic cholinesterases to ecgonine methyl ester can account for up to 32–49% of an administered cocaine dose.^{95,97} Finally, *N*-demethylation to norcocaine, mediated by CYP3A4, makes up <10% of cocaine's biotransformation.^{95,98,99} Other metabolites (e.g., anhydroecgonine methyl ester, *p*-hydroxy cocaine) are also produced in the metabolism of cocaine, although in smaller amounts.

Interactions between cocaine and antiretrovirals have not been described. Theoretically, inhibition of CYP3A4 may increase concentrations of the parent compound by blocking a route of cocaine metabolism. However, given that *N*-demethylation is a relatively small component of cocaine metabolism, such an interaction would not be expected to increase the risk of cocaine toxicity. An exception may occur in patients who are also cholinesterase defi-

cient, since they lack the complementary enzymes necessary to metabolize the excess cocaine burden.¹⁰⁰

Inhibition of the CYP3A4 isoform would consequently result in decreased production of norcocaine; norcocaine is thought to play a critical role in mediating the hepatotoxicity of cocaine.^{101,102} In vitro studies¹⁰³ documenting the protective effect of 3A4 inhibitors against cocaine-elicited hepatotoxicity lend credence to this notion. Thus, it is possible that inhibition of CYP3A4 by some antiretrovirals may theoretically ameliorate the hepatotoxicity associated with cocaine, although it should be stressed that there are no clinical data to support this. Furthermore, such postulated effects may not be clinically significant in the context of other factors, such as concomitant hepatitis B or C infection.

However, if inhibition of CYP3A4 is theoretically protective against cocaine-mediated liver injury, the reverse may be true. That is, induction of CYP3A4 by nevirapine or efavirenz may lead to increasing amounts of norcocaine being formed, potentially increasing the risk of hepatotoxicity. Again, further research is necessary to clarify the nature and consequences of interactions between enzyme inducers and cocaine.

Table 4. Postulated and Actual Interactions Between Commonly Used Opiate Drugs and Antiretrovirals⁷⁹⁻⁹¹

Drug	Metabolism	Actual/Theoretical Interaction	Potential Significance	Recommendation
Codeine	3 pathways: glucuronidation to codeine-6-glucuronide (~70%); <i>N</i> -demethylation to norcodeine (3A4) (<10%); <i>O</i> -demethylation to morphine (2D6) (10–15%) ⁸²⁻⁸⁷	↓ morphine concentrations: 2D6 inhibition (inhibit <i>O</i> -demethylation); 3A4/glucuronide induction (less substrate available for 2D6) ↑ morphine concentrations: 3A4 inhibition (shunting of substrate to 2D6 pathway)	opiate withdrawal, loss of analgesia opiate toxicity	monitor for signs/symptoms of opiate withdrawal (see Meperidine); reassess level of analgesia monitor for signs/symptoms of opiate toxicity (e.g., miosis, drowsiness, ↓ rate and depth of respiration, nausea, vomiting, constipation, hypotension, bradycardia)
Meperidine	2 pathways: hydrolysis to meperidinic acid by liver carboxylesterases; demethylation by CYP450 system to normeperidine (exact isoenzyme unknown) ^{79,80}	AUC of meperidine ↓ 67% and AUC of normeperidine ↑ 47% in open-label study ⁸¹ of 8 volunteers receiving treatment with meperidine 50 mg prior to and following 10 d of treatment with ritonavir	possible opiate withdrawal, loss of analgesia; possible ↑ risk of seizures with normeperidine accumulation	monitor for signs/symptoms of opiate withdrawal (e.g., lacrimation, rhinorrhea, diaphoresis, restlessness, insomnia, dilated pupils, piloerection); reassess level of analgesia; avoid combination of ritonavir and meperidine in pts. with renal failure and pts. who use meperidine regularly for analgesia or recreationally due to risk of neurotoxicity
Morphine	glucuronidated to M6G and M3G ⁸⁹⁻⁹¹	increase glucuronidation: accelerate morphine metabolism, ↓ concentrations of morphine, ↑ concentrations of pharmacologically active M6G	possible opiate withdrawal, and loss of analgesia, although may be attenuated by ↑ formation of M6G	monitor for signs/symptoms of opiate withdrawal (see Meperidine); reassess level of analgesia
Oxycodone	3 pathways: CYP2D6 to oxymorphone; CYP3A4 to noroxycodone; ketoreductase ⁸⁸	↓ oxymorphone concentrations: inhibition of 2D6; 3A4 induction (less substrate for 2D6 pathway) ↑ oxymorphone concentrations: 3A4 inhibition (shunting to 2D6 pathway)	possible opiate withdrawal and loss of analgesia, although ↓ oxymorphone concentrations do not appear to alter pharmacodynamics of oxycodone; possible opiate toxicity	monitor for signs/symptoms of opiate withdrawal (see Meperidine); reassess level of analgesia monitor for signs/symptoms of opiate toxicity (see Codeine)

M3G = morphine-3-glucuronide; M6G = morphine-6-glucuronide.

Heroin is rapidly metabolized to 6-monoacetylmorphine and morphine by plasma and liver esterases, respectively. Maximal blood concentrations of heroin and 6-monoacetylmorphine are attained within minutes and are cleared rapidly, while morphine concentrations increase and decrease more slowly.¹⁰⁴⁻¹⁰⁷ Thus, potential interactions of concern may be similar to those noted with morphine (Table 4).

Benzodiazepines

Benzodiazepines remain among the most commonly prescribed psychotropic drugs. In Canada, the overall prevalence of benzodiazepine use for anxiety in the 1990s was estimated at roughly 8% of the adult population, while about 2.5% of adults were prescribed this group of drugs for insomnia.¹⁰⁸ Benzodiazepines may be used recreationally either alone or, more commonly, in the setting of multiple drug abuse. Potential abuses of benzodiazepines include moderating the effects of stimulants, allaying withdrawal symptoms from other recreational substances, acting as disinhibitory agents, or augmenting the effects of other recreational drugs. As a class, benzodiazepines are extensively metabolized by the liver, with individual agents metabolized predominantly by either the CYP450 system or glucuronyltransferases.

Midazolam, triazolam, and alprazolam are metabolized mainly by CYP3A4.^{109,110} Interactions with PIs, delavirdine, and, possibly, efavirenz are thus likely to produce increased concentrations of these compounds and place patients at risk of toxicity such as extreme sedation and respiratory depression. Pharmacokinetic studies and case reports documenting such interactions are summarized in Table 5.¹¹¹⁻¹¹⁵ It is interesting to note that conflicting data exist regarding the interaction between alprazolam and ritonavir. While Frye et al.¹¹¹ noted a reduction in alprazolam exposure and relatively little change in pharmacodynamic effect following 12 days of ritonavir, subsequent work by Greenblatt et al.¹¹² found that acute exposure to ritonavir reduced alprazolam clearance and enhanced alprazolam's pharmacodynamic properties. This discrepancy may be accounted for by the fact that ritonavir, over time, may induce as well as inhibit CYP3A4.¹¹⁶ Thus, acute exposure to ritonavir may place patients at increased risk for alprazolam toxicity, while longer-term exposure to ritonavir may result in a loss of anxiety and possible withdrawal in patients who are using alprazolam recreationally. A longer-term study is necessary to further clarify the time course and nature of the interaction between alprazolam and ritonavir.

Additional information is also required to clarify the safety of using midazolam with PIs. Palkama et al.¹¹³ concluded that, aside from the possibility of a longer sedative effect, the use of bolus doses of intravenous midazolam with saquinavir is likely safe. However, other investigators¹¹⁴ reported on a patient who experienced prolonged sedation secondary to the combination of midazolam and saquinavir; their experience warrants that patients receiving the combination should be closely monitored. Data with other PIs are lacking. The use of midazolam with PIs and delavirdine

should be avoided if possible, given the risk of prolonged sedation and respiratory depression associated with large increases in midazolam concentrations. Although formal pharmacokinetic studies are lacking, similar interactions between clonazepam and flunitrazepam and PIs are possible, since both agents are substrates of CYP3A4.^{117,118} As well, caution should be exercised with diazepam, particularly in combination with ritonavir, since both the 3A4 and 2C19 systems appear to be important in its metabolism.^{119,120} In contrast, nevirapine and efavirenz may put patients who are using midazolam, triazolam, alprazolam, clonazepam, and flunitrazepam at risk for loss of effect and/or withdrawal due to their 3A4 inductive potential.

Interactions between lorazepam, oxazepam, or temazepam and antiretrovirals differ from those described above, since these members of the benzodiazepine family are metabolized primarily by glucuronidation.^{121,122} Thus, drugs that increase the activity of glucuronyltransferases (i.e., ritonavir, nelfinavir) may accelerate the metabolism of these compounds, resulting in lower drug exposure. Although reports are lacking, concomitant use of lorazepam, oxazepam, or temazepam with either ritonavir or nelfinavir may decrease the anxiolytic effect of these agents or precipitate symptoms consistent with benzodiazepine withdrawal reaction due to the aforementioned interaction. A higher dose of the benzodiazepine may be necessary to compensate for the interaction.

Tetrahydrocannabinol

Tetrahydrocannabinol (THC), the active ingredient of smoked marijuana, remains a commonly used recreational agent. In Canada, 23.1% of surveyed adults had used marijuana more than once in their lives, and current use was estimated at 7.4%.¹²³ In the context of HIV/AIDS, smoked marijuana or THC-containing preparations may also be used for antiemetic or appetite stimulation purposes.

THC is metabolized in humans by microsomal oxidation to several hydroxylated metabolites, among them 11-hydroxy-THC, which is pharmacologically active. Concentrations of 11-hydroxy-THC vary with the route of administration, with oral administration generally producing more of the active metabolite than inhaled THC due to significant first-pass effect. Limited data suggest that CYP3A and 2C9 isoenzymes are involved in microsomal oxidation of THC.¹²⁴⁻¹²⁷ Although inhibition of CYP3A4 or 2C9 may decrease the formation of pharmacologically active metabolites, the effects of THC are unlikely to be significantly attenuated, as THC itself is active and will be more bioavailable. Increased THC concentrations may lead to dose-related effects including frank hallucinations, delusions, paranoid thinking, accentuation of altered time sense, anxiety, panic, depersonalization, loss of insight, orthostatic hypotension, and increased heart rate. Furthermore, inhibition of THC metabolism to 11-hydroxy-THC may be important only in the setting of oral administration, since just trace amounts of the active metabolite are present following smoking.

Induction of CYP3A4 may increase the formation of the pharmacologically active metabolite; however, the conversion of active metabolite to its inactive counterparts may also be accelerated, thereby decreasing the duration of THC effect. This action may be more clinically important with oral THC administration due to its large first-pass effect. The impact of THC on the pharmacokinetics of indinavir and nelfinavir has been evaluated in a small, randomized, placebo-controlled study.¹²⁸ Patients on stable indinavir or nelfinavir therapy were randomized to receive either THC 3.95% cigarettes, THC 2.5-mg capsules, or

placebo, each administered 3 times a day. Nelfinavir and indinavir concentrations were determined prior to and on day 14 of THC use. A statistically significant 14% reduction in indinavir maximum concentration was observed with smoked THC. As well, smoked THC significantly reduced the ratio of M8 (active metabolite of nelfinavir) to nelfinavir by 18% ($p = 0.039$). However, as mentioned previously, reductions in M8 concentrations do not appear to be clinically important. Furthermore, a significant reduction ($p = 0.025$) in M8 concentrations relative to baseline was observed in patients receiving placebo. Other

Table 5. Interactions Between Antiretrovirals and Benzodiazepines¹¹¹⁻¹¹⁵

Reference	Study Type	Patients	Nature of Interaction	Recommendation
Alprazolam				
Frye et al. (1997) ¹¹¹	pharmacokinetics of alprazolam 1.0 mg determined prior to ritonavir treatment and after 12 d of escalating ritonavir doses	healthy volunteers	alprazolam AUC ↓ 12%; ritonavir did not produce clinically important impairment and had no effect on peak sedation; combination appeared to prolong sedation	short-term PI administration: monitor for alprazolam toxicity (e.g., sedation, dizziness, ataxia, respiratory depression) with acute administration of ritonavir and, possibly, other PIs and delavirdine
Greenblatt et al. (2000) ¹¹²	double-blind, randomized, 2-way crossover study of pharmacokinetics of alprazolam 1.0 mg with ritonavir or placebo	10 healthy volunteers	alprazolam $t_{1/2}$ ↑ from 13 to 30 h ($p < 0.005$); alprazolam clearance ↓ to 41% of control values with ritonavir ($p < 0.001$); ritonavir ↑ benzodiazepine agonist effects (e.g., sedation, performance impairment)	chronic ritonavir administration: monitor for alprazolam withdrawal (e.g., anxiety, dysphoria, nausea, muscle twitching, insomnia, panic/paranoia, convulsions) and loss of anxiolysis with chronic ritonavir use
Midazolam				
Palkama et al. (1999) ¹¹³	randomized, double-blind, crossover study; pts. received treatment with saquinavir-SGC 1200 mg or placebo 3 times/d for 5 d; on day 3, received midazolam 7.5 mg po or 0.05 mg/kg iv over 2 min; on day 5, second dose of midazolam given, alternating routes of administration	12 healthy volunteers	po midazolam: saquinavir ↑ C_{max} 2.3-fold ($p < 0.001$); ↑ AUC 5-fold ($p < 0.01$), ↑ $t_{1/2}$ from 4.3 to 10.9 h ($p < 0.01$), ↑ bioavailability from 41% to 90% ($p < 0.001$); sedative effects of po midazolam profoundly enhanced iv midazolam: saquinavir ↓ clearance; by 56% ($p < 0.001$), ↑ $t_{1/2}$ from 4.1 to 9.5 h ($p < 0.001$); authors suggest ↓ initial midazolam dose by 50% when given by infusion, followed by careful titration	midazolam contraindicated with PIs, delavirdine, and efavirenz; if necessary to use combination, consider dose ↓ of 50% with careful titration and monitoring for toxicity (e.g., extreme/prolonged sedation, respiratory depression, hypotension)
Merry et al. (1997) ¹¹⁴	case report: pt. received midazolam 5.0 mg iv for bronchoscopy with no ill effect; 8 wk later, pt. received second dose for bone marrow aspirate and biopsy; between the first and second dose, pt. began saquinavir-HGC-based HAART regimen	32-y-old man with advanced HIV	following second dose, pt. did not wake spontaneously and required flumazenil due to prolonged sedation, possibly as a result of an interaction with saquinavir	
Triazolam				
Greenblatt et al. (2000) ¹¹⁵	double-blind, randomized, crossover study of pharmacokinetics of triazolam 0.125 mg concurrent with ritonavir or placebo	6 healthy volunteers	ritonavir ↑ triazolam $t_{1/2}$ from 3 to 41 h ($p < 0.005$) and ↓ triazolam clearance to 4% of control values ($p < 0.005$); sedation and performance impairment magnified by ritonavir	avoid combination of triazolam and PIs, delavirdine, or efavirenz
C_{max} = maximum plasma concentration; HAART = highly active antiretroviral therapy; HGC = hard-gel capsule; PI = protease inhibitor; SGC = soft-gel capsule; $t_{1/2}$ = half life.				

variables did not change significantly, nor did oral THC produce significant changes in indinavir or nelfinavir pharmacokinetics. The long-term clinical consequence of these changes is likely negligible, especially with the increasing use of boosted PI regimens. There are no reports documenting the impact of antiretrovirals on THC pharmacokinetics or pharmacodynamics. The nature of such an interaction would be difficult to predict, as several variables, including route of administration and the concentration of THC smoked, may confound the outcome.

Considering the widespread use of smoked and oral THC derivatives for appetite stimulation and control of nausea and vomiting, and the lack of reports documenting deleterious effects secondary to the combination of THC and PIs, a clinically significant drug interaction may not exist when THC is used in moderate amounts. Patients who use THC and are beginning antiretroviral therapy should be warned about possible accentuation of the effects of THC, and that they may need to use less THC for the same effect following treatment initiation.

Alcohol

Ethanol metabolism is mediated chiefly by the enzymes alcohol dehydrogenase (formation of acetaldehyde) and aldehyde dehydrogenase. Since 1 of the 2 main metabolites of abacavir is a carboxylate derivative, the formation of which is catalyzed by the alcohol dehydrogenase enzyme, an interaction between ethanol and abacavir is possible due to competition for metabolism. A randomized, open-label, crossover study¹²⁹ confirmed the existence of such an interaction. Twenty-five HIV-positive patients were randomized to receive either a single dose of abacavir 600 mg, ethanol 0.7 g/kg, or the combination of abacavir and ethanol, with a washout period of 7 days between treatments. Concomitant administration of ethanol and abacavir resulted in a statistically significant 41% increase in abacavir AUC (CI 1.35 to 1.48); no changes in ethanol blood concentrations were observed. The increase in abacavir AUC is unlikely to be clinically significant, as the concentrations were within the ranges observed in previous pharmacokinetic studies of abacavir that employed higher abacavir doses and did not demonstrate additional safety issues.¹²⁸

Acute administration of alcohol may increase plasma concentrations of other substrates by inhibiting isoforms such as CYP2D6 and 2C19.¹³⁰ On the other hand, chronic administration may reduce plasma concentrations of drugs metabolized by CYP2E1 and 3A.^{131,132} Thus, there is potential for induction of PI and NNRTI metabolism with chronic alcohol use. Such an interaction may result in subtherapeutic concentrations of these agents, predisposing to resistance and compromising antiretroviral efficacy over time. However, there are currently no data documenting such an interaction. Appropriately conducted pharmacokinetic studies are necessary to confirm the existence of an interaction between antiretrovirals and chronic alcohol use and to clarify appropriate management strategies.

Discussion

The increasing numbers of available PIs and NNRTIs and the identification of various isoforms of the CYP450 enzyme system have heightened awareness about the significance of drug interactions in the HIV population. However, recreational drugs are often not considered by both clinicians and patients when reviewing a particular medication regimen for potential interactions. One of the inherent concerns associated with recreational drug use is that the margin of safety for many of these substances is often poorly defined, and quality control is often highly variable. Thus, factors that may lead to unpredictable drug concentrations can further increase the risk of adverse outcomes. Given the increasing incidence of HIV infection among substance users and the increasing use of complex combination antiretroviral regimens, the risk of adverse drug interactions with possibly fatal consequences cannot be overlooked or ignored. Clinicians should, therefore, strive to gather information about recreational drug use as part of a comprehensive medication history. Reassuring the patient that confidentiality will be respected and the use of open-ended questions directed in a nonthreatening and nonjudgmental manner will facilitate the information-gathering process.

Much of the information presented in this article is largely extrapolated from *in vitro* pharmacokinetic experiments, case reports, or animal model studies. There are obviously many limitations in applying such data to clinical practice settings. With case reports, information is often anecdotal in nature. Patients' own recall bias is an obvious limitation, making direct causality difficult to establish. Even when *in vitro* or *in vivo* data are available, results often may not be directly extrapolated to clinical situations. For instance, much of the interaction information for ritonavir is based on full-dose (i.e., 600 mg twice daily) studies. However, ritonavir is now frequently used at lower doses (e.g., 100–200 mg twice daily) as a pharmacokinetic boosting agent. Ritonavir can inhibit CYP450 activity and increase protease trough concentrations in a dose-related manner.¹³³ Therefore, the frequency, extent, and/or clinical significance of interactions with ritonavir 100 mg twice daily may be lower compared with higher doses of ritonavir. As an example, when efavirenz was added to a combination of amprenavir 600 mg twice daily plus ritonavir 100 mg twice daily, amprenavir concentrations were decreased by almost 80%; however, when the ritonavir dose was increased to 200 mg twice daily, amprenavir concentrations remained stable in the presence of efavirenz.¹³⁴

These confounding factors highlight the importance of designing interaction studies that accurately reflect situations encountered in clinical practice. However, due to legal and ethical constraints, it is highly unlikely that rigorous, prospective, controlled interaction studies between antiretrovirals and recreational drugs will ever be conducted. As such, these limited data may serve as a tool for clinicians in anticipating and hopefully averting potential detrimental interactions with recreational drugs.

Summary

Adverse interactions between agents commonly prescribed in HIV and recreational drugs can occur, and may possibly be associated with serious clinical consequences. This issue highlights the need for clinicians to obtain thorough patient histories on both prescription as well as recreational drug use and to counsel and/or adjust therapeutic regimens when required to minimize the risk of morbidity or mortality.

Tony Antoniou PharmD, Pharmacist, HIV Program/Inner City Health, St. Michael's Hospital, Toronto, Ontario, Canada

Alice Lin-in Tseng PharmD, Pharmacist, Immunodeficiency Clinic, Toronto General Hospital, Toronto; Assistant Professor, Faculty of Pharmacy, University of Toronto, Toronto

Reprints: Alice Lin-in Tseng PharmD, Immunodeficiency Clinic, CW-G315, Toronto General Hospital, 101 College St., Toronto, Ontario M5G 2C4, Canada, FAX 416/340-4890, E-mail alice.tseng@uhn.on.ca

References

- Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med* 1998;338:853-60.
- Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcic S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advance HIV Disease Ritonavir Study Group. *Lancet* 1998;351:543-9.
- Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. *N Engl J Med* 1997;337:725-33.
- Van Cleef G, Fisher EJ, Polk RE. Drug interaction potential with inhibitors of HIV protease. *Pharmacotherapy* 1997;17:774-8.
- Preston SL, Postelnick M, Purdy BD, Petrolati J, Aasi H, Stein DS. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy (letter). *AIDS* 1998;12:228-30.
- von Moltke LL, Greenblatt DY, Grassi JM, Granda BW, Duan SX, Fogelman SM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. *J Clin Pharmacol* 1998;38:106-11.
- von Moltke LL, Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX, Daily JP, et al. Inhibition of cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. *J Clin Pharmacol* 2001;41:85-91.
- Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. *JAMA* 1997;277:145-53.
- Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. *Clin Pharmacokinet* 1997;32:194-209.
- Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with HIV. *Clin Infect Dis* 1996;23:685-93.
- Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. *Clin Pharmacokinet* 1999;36:289-304.
- Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. *Ann Pharmacother* 1997;31:1040-58.
- Product monograph. Sustiva (efavirenz). Princeton, NJ: Bristol Myers Squibb Pharma, February 2002.
- Patrick DM, Strathdee SA, Currie S, Pitchford W, Rekart ML, FitzGerald M, et al. Incidence of HIV in the Vancouver IDU Study Cohort. Presented at: 6th Annual Canadian Conference on HIV/AIDS Research, Ottawa, May 22-26, 1997.
- Clarke S, Quah S, Courtney G, Lyons F, Bergin C, Mulcahy F. A rapidly increasing incidence of HIV infection in injecting drug users (IDU) in Ireland (abstract). Presented at: 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4-8, 2001.
- HIV/AIDS surveillance report. Atlanta: Centers for Disease Control and Prevention, 2001;13:1-41.
- Geduld J, Archibald C. National trends of HIV and AIDS in Canada. *Canada Commun Dis Rep* 2000;26:193-201.
- Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. *Lancet* 1998;352:1751-2.
- Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. *Clin Pharmacokinet* 1997;32:210-58.
- Jacobs MR, O'Brien Fehr K. *Drugs and drug abuse: a reference text*. Toronto: Alcoholism and Drug Addiction Research Foundation, 1987.
- Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, et al. The demethylation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). *Biochem Pharmacol* 1994;47:1151-6.
- Colado MI, Williams JL, Green AR. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4-methylenedioxymethamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. *Br J Pharmacol* 1995;115:1281-9.
- Kreth K, Kovar K, Schwab M, Zangar UM. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related drugs. *Biochem Pharmacol* 2000;15:1563-71.
- Sherlock K, Wolff K, Hay AW, Conner M. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. *J Accid Emerg Med* 1999;16:194-7.
- Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. *Drug Metab Dispos* 2001;29:100-2.
- Lin LY, Kumagai Y, Hiratsuka A, Narimatsu S, Suzuki T, Funae Y, et al. Cytochrome P450D2 isozymes catalyze the 4-hydroxylation of methamphetamine enantiomers. *Drug Metab Dispos* 1995;23:610-4.
- Geertsen S, Foster BC, Wilson DL, Cyr TD, Casley W. Metabolism of methoxyphenamine and 2-methoxyamphetamine in P450D6-transfected cells and cell preparations. *Xenobiotica* 1995;25:895-906.
- Lin LY, Di Stefano EW, Schmitz DA, Hsu L, Ellis SW, Lennard MS, et al. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. *Drug Metab Dispos* 1997;25:1059-64.
- Lettieri JT, Fung HL. Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. *J Pharmacol Exp Ther* 1979;208:7-11.
- Lettieri JT, Fung HL. Absorption and first pass metabolism of 14C-gamma-hydroxybutyric acid. *Res Commun Chem Pathol Pharmacol* 1976;13:425-37.
- Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. *Arch Intern Med* 1999;159:2221-4.
- White PF, Way WL, Trevor AJ. Ketamine — its pharmacology and therapeutic uses. *Anesthesiology* 1982;56:119-36.
- Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y, et al. Involvement of CYP2B6 in *n*-demethylation of ketamine in human liver microsomes. *Drug Metab Dispos* 2001;29:887-90.
- Loch JM, Potter J, Bachman KA. The influence of anesthetic agents on rat hepatic cytochromes P450 in vivo. *Pharmacology* 1995;50:146-53.
- Menuguz A, Fortuna S, Lorenzini P, Volpe MT. Influence of urethane and ketamine on rat hepatic cytochrome P450 in vivo. *Exp Toxicol Pathol* 1999;51:392-6.
- Laurenzana EM, Owens SM. Metabolism of phencyclidine by human liver microsomes. *Drug Metab Dispos* 1997;25:557-63.
- Shelnutt SR, Badger TM, Owens SM. Phencyclidine metabolite irreversible binding in the rat: gonadal steroid regulation and CYP2C11. *J Pharmacol Exp Ther* 1996;277:292-8.
- Crowley JR, Hollenberg PF. Mechanism-based inactivation of rat liver cytochrome P450B1 by phencyclidine and its oxidative product, the iminium ion. *Drug Metab Dispos* 1995;23:786-93.
- Inoue T, Niwaguchi T, Murata T. Effects of inducers and/or inhibitors on metabolism of lysergic acid diethylamide in rat liver microsomes. *Xenobiotica* 1980;10:913-20.
- Cai J, Henion J. Elucidation of LSD in vitro metabolism by liquid chromatography and capillary electrophoresis coupled with tandem mass spectrometry. *J Anal Toxicol* 1996;20:27-37.
- Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, et al. Involvement of cytochrome P450 3A4 enzyme in the *N*-demethylation of methadone in human liver microsomes. *Chem Res Toxicol* 1996;9:365-73.

42. Foster DJ, Somogyi AA, Bochner F. Methadone *N*-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. *Br J Clin Pharmacol* 1999;47:403-12.
43. Eap CB, Broly F, Mino A, Hammig R, Deglon JJ, Uehlinger C, et al. Cytochrome P450 2D6 genotype and methadone steady-state concentrations. *J Clin Psychopharmacol* 2001;21:229-34.
44. Gerber JG, Rhodes RJ. Cytochrome P450 2B6 metabolizes methadone preferentially and stereospecifically. An explanation of drug interaction with antiretroviral drugs (abstract 2.2). Presented at: First International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands, March 30–31, 2000:14.
45. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. *Br J Clin Pharmacol* 2001;51:213-7.
46. Heelon MW, Meade LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. *Pharmacotherapy* 1999;19:471-2.
47. Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB. Efavirenz decreases methadone blood concentrations. *AIDS* 2000;14:1291-2.
48. Pinzani V, Faucher V, Peyriere H, Blayac JP. Methadone withdrawal symptoms with nevirapine and efavirenz (letter). *Ann Pharmacother* 2000;34:405-7.
49. Staszewski S, Haberl A, Gute P, Nisius G, Miller V, Carlebach A. Nevirapine/didanosine/lamivudine once daily in HIV-1 infected intravenous drug users. *Antiviral Ther* 1998;3:55-6.
50. Altice FL, Friedland GH, Cooney E. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. *AIDS* 1999;13:957-62.
51. Otero MJ, Fuertes A, Sanchez R, Luna G. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. *AIDS* 1999;13:1004-5.
52. Geletko SM, Erickson AD. Decreased methadone effect after ritonavir initiation. *Pharmacotherapy* 2000;20:93-4.
53. Hsyu PH, Lillibridge JH, Maroldo L, Weiss WR, Kerr BM. Pharmacokinetic and pharmacodynamic interactions between nelfinavir and methadone (abstract 87). Presented at: 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30–February 2, 2000.
54. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, et al. The effect of ritonavir/saquinavir on the stereoselective pharmacokinetics of methadone: results of AIDS clinical trials group (ACTG) 401. *J Acq Immune Def Synd* 2001;27:153-60.
55. Hendrix C, Wakeford J, Wire MB, Bigelow G, Cornell E, Christopher J, et al. Pharmacokinetic and pharmacodynamic evaluation of methadone enantiomers following co-administration with amprenavir in opioid-dependent subjects (abstract 1649). Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17–20, 2000:335.
56. Maroldo L, Manocchio S, Arstein A, Weiss W. Lack of effect of nelfinavir mesylate on maintenance methadone dose requirement (abstract WePeB4120). Presented at: XIII International AIDS Conference, Durban, South Africa, July 9–14, 2000:60.
57. McCance-Katz EF, Farber S, Selwyn PA, O'Connor A. Decrease in methadone levels with nelfinavir mesylate (letter). *Am J Psychiatry* 2000;157:481.
58. Beauverie P, Taburet AM, Dessalles MC, Furlan V, Touzeau D. Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors. *AIDS* 1998;12:2510-1.
59. Rainey PM, Friedland G, McCance-Katz EF, Andrews L, Mitchell SM, Charles C, et al. Interaction of methadone with didanosine and stavudine. *J Acq Immune Def Synd* 2000;24:241-8.
60. Schwartz EL, Brechbuhl AB, Kahl P, Miller MA, Selwyn PA, Friedland GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. *J Acq Immune Def Synd* 1992;5:619-26.
61. McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (AIDS clinical trials group 262). *J Acq Immune Def Synd* 1998;18:435-43.
62. Sellers E, Lam R, McDowell J, Corrigan B, Hedayetullah N, Somer G, et al. The pharmacokinetics of abacavir and methadone following coadministration: CNA1012 (abstract 663). Presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26–28, 1999:25.
63. Booker B, Smith P, Forrest A, Difrancesco R, Morse G, Cottone P, et al. Lack of effect of methadone (MET) on the pharmacokinetics (PK) of delavirdine (DLV) & *N*-delavirdine (abstract A 490). Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001:14.
64. Boffito M, Rossati A, Dal Conte I, Reynolds H, Gibbons S, Back D, et al. Opiate withdrawal syndrome in new efavirenz recipients under methadone maintenance regimen (abstract). Presented at: 1st IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, July 8–11, 2001.
65. Smith PF, Booker BM, Difrancesco R, Morse GD, Cottone PF, Murphy MK, et al. Effect of methadone or LAAM on the pharmacokinetics of nelfinavir & M8 (abstract A-491). Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001:14.
66. Brown LS, Chu M, Aug C, Dabo S. The use of nelfinavir and two nucleosides concomitantly with methadone is effective and well-tolerated in HepC co-infected patients (abstract I-206). Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001:311.
67. Shelton MJ, Cloen D, Berenson C, Esch A, Brewer J, Hewitt R. Pharmacokinetics (PK) of once daily (QD) saquinavir/ritonavir (SQV/RTV): effects on unbound methadone and α -acid glycoprotein (AAG) (abstract A-492). Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001:14.
68. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. *Clin Infect Dis* 2001;33:1595-7.
69. Cantilena L, McCrea J, Blazes D, Winchell G, Carides A, Royce C, et al. Lack of a pharmacokinetic interaction between indinavir and methadone (abstract PI-74). *Clin Pharmacol Ther* 1999;65:135.
70. Clarke S, Mulcahy F, Bergin C, Reynolds H, Boyle N, Barry MG, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir–ritonavir. *Clin Infect Dis* 2002;34:1143-5.
71. Munsiff AV, Patel J. Regimens with once daily ritonavir + Fortovase are highly effective in PI-experienced HIV-HCV co-infected patients on methadone (abstract 684). Presented at: 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, October 25–28, 2001.
72. Friedland G, Rainey P, Jatlow P, Andrews L, Damle B, McCance-Katz E. Pharmacokinetics (pK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs chewable tablet formulation in patients (pts) on chronic methadone therapy (abstract TuPeB4548). Presented at: XIV International AIDS Conference, Barcelona, July 7–12, 2002, vol 1:402-3.
73. Guibert A, Furlan V, Martino J, Taburet AM. In vitro effect of HIV protease inhibitors on methadone metabolism (abstract). Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997.
74. Hsu A, Granneman GR, Carothers L, Dennis S, Chiu Y-L, Valdes J, et al. Ritonavir does not increase methadone exposure in healthy volunteers (abstract 342). Presented at: 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February 1–5, 1998.
75. Boulton DW, Arnaud P, DeVane CL. A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio. *Br J Clin Pharmacol* 2001;51:350-4.
76. Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. *Toxicology* 1997;117:13-23.
77. Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. *Br J Clin Pharmacol* 1993;35:30-4.
78. Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. *Antimicrob Agents Chemother* 2001;45:1086-93.
79. Edwards DJ, Svensson CK, Visco JP, Lalka D. Clinical pharmacokinetics of pethidine. *Clin Pharmacokinet* 1982;7:421-33.
80. Zhang J, Burnell JC, Dumaul N, Bosron WF. Binding and hydrolysis of meperidine by human liver carboxylesterase hCE-1. *J Pharmacol Exp Ther* 1999;290:314-8.
81. Piscitelli S, Rock-Kress D, Bertz R, Pau A, Davey R. The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. *Pharmacotherapy* 2000;20:549-53.

82. Dayer P, Desmeules J, Striberni R. In vitro forecasting of drugs that may interfere with codeine bioactivation. *Eur J Drug Metab Pharmacol* 1992;17:115-20.
83. Poulsen L, Brosen K, Arendt-Neilsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. *Eur J Clin Pharmacol* 1996;51:289-95.
84. Caraco Y, Tateishi T, Guengerich FP, Wood AJ. Microsomal codeine *N*-demethylation: cosegregation with cytochrome P4503A4 activity. *Drug Metab Dispos* 1996;24:761-4.
85. Yue QY, Sawe J. Different effects of inhibitors on the *O*- and *N*-demethylation of codeine in human liver microsomes. *Eur J Clin Pharmacol* 1997;1997:41-7.
86. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and mitotic effects. *J Pharmacol Exp Ther* 1997;281:330-6.
87. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. *J Pharmacol Exp Ther* 1996;278:1165-74.
88. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. *Clin Pharmacol Ther* 1998;64:603-11.
89. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. *Drug Metab Dispos* 1997;25:1-4.
90. Fromm MF, Eckhardt K, Li S, Schanzle G, Hofmann U, Mikus G, et al. Loss of analgesic effect of morphine due to coadministration of rifampin. *Pain* 1997;72:261-7.
91. Osborne R, Joel S, Trew D, Slevin M. Analgesic activity of morphine-6-glucuronide (letter). *Lancet* 1988;1:828.
92. Chaisson MA, Stoneburner RL, Hildebrandt DS, Ewing WE, Telzak EE, Jaffe HW. Heterosexual transmission of HIV-1 associated with the use of smokable freebase cocaine (crack). *AIDS* 1991;5:1121-6.
93. Edlin BR, Irwin KL, Faruque S, McCoy CB, Word C, Serrano Y, et al. Intersecting epidemics — crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. *N Engl J Med* 1994;331:1422-7.
94. Nuttbrock L, Rosenblum A, Magura S, McQuiston HL, Joseph H. The association between cocaine use and HIV/STDs among soup kitchen attendees in New York City. *J Acq Immune Def Synd* 2000;25:86-91.
95. Inaba T, Stewart DJ, Kalow W. Metabolism of cocaine in man. *Clin Pharmacol Ther* 1978;23:547-52.
96. Cone EJ, Tsadik A, Oyler J, Darwin WD. Cocaine metabolism and urinary excretion after different routes of administration. *Ther Drug Monit* 1998;20:556-60.
97. Stewart DJ, Inaba T, Lucassen M, Kalow W. Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases. *Clin Pharmacol Ther* 1979;25:464-8.
98. Leduc BW, Sinclair PR, Shuster L, Sinclair JF, Evans JE, Greenblatt DJ. Norcocaine and *N*-hydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3A4. *Pharmacology* 1993;46:294-300.
99. Ladona MG, Gonzalez ML, Rane A, Peter RM, de la Torre R. Cocaine metabolism in human fetal and adult liver microsomes is related to cytochrome P450 3A expression. *Life Sci* 2000;68:431-43.
100. Hoffman RS, Henry GC, Howland MA, Weisman RS, Weil L, Goldfrank LR. Association between life-threatening cocaine toxicity and plasma cholinesterase activity. *Ann Emerg Med* 1992;21:247-53.
101. Ndikum-Moffor FM, Schoeb TR, Roberts SM. Liver toxicity from norcocaine nitroxide, an *N*-oxidative metabolite of cocaine. *J Pharmacol Exp Ther* 1998;284:413-9.
102. Roberts SM, Harbison RD, James RC. Human microsomal *N*-oxidative metabolism of cocaine. *Drug Metab Dispos* 1991;19:1046-51.
103. Pellinen P, Honkakoski P, Stenback F, Niemitz M, Alhava E, Pelkonen O, et al. Cocaine *N*-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. *Eur J Pharmacol* 1994;270:35-43.
104. Lockridge O, Mottershaw-Jackson N, Eckerson HW, La Du BN. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. *J Pharmacol Exp Ther* 1980;21:1-8.
105. Inturrisi CE, Max MB, Foley KM, Schultz M, Shin SU, Houde RW. The pharmacokinetics of heroin in patients with chronic pain. *N Engl J Med* 1984;310:1213-7.
106. Kamendulis LM, Brzezinski MR, Pindel EV, Bosron WF, Dean RA. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. *J Pharmacol Exp Ther* 1996;279:713-7.
107. Jenkins AJ, Keenan RM, Henningfield JE, Cone EJ. Pharmacokinetics and pharmacodynamics of smoked heroin. *J Anal Toxicol* 1994;18:317-30.
108. Busto UE. Benzodiazepines: the science and the myths. *Can J Clin Pharmacol* 1999;6:185-6.
109. Kronback T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIa4. *Mol Pharmacol* 1989;36:89-96.
110. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI. Alprazolam is another substrate for human cytochrome P450-3A isoforms (letter). *J Clin Psychopharmacol* 1998;18:256.
111. Frye R, Bertz R, Granneman GR, Qian J, Lamm J, Dennis S, et al. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam (abstract A59). Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997.
112. Greenblatt D, Moltke L, Harmatz J, Durol AL, Daily JP, Graf JA, et al. Alprazolam–ritonavir interaction: implications for product labeling. *Clin Pharmacol Ther* 2000;67:335-41.
113. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. *Clin Pharmacol Ther* 1999;66:33-9.
114. Merry C, Mulcahy F, Barry M, Gibbons S, Back D. Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease (letter). *AIDS* 1997;11:268-9.
115. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. *J Acq Immune Def Synd* 2000;24:129-36.
116. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. *J Clin Psychopharmacol* 1999;19:293-6.
117. Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA. Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. *Fundam Clin Pharmacol* 1993;7:69-75.
118. Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt DJ. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. *Drug Metab Dispos* 2001;29:133-40.
119. Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ, et al. Human liver microsomal diazepam metabolism using cDNA expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. *Xenobiotica* 1996;26:1155-66.
120. Jung F, Richardson TH, Raucy JL, Johnson EF. Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam *N*-demethylases. *Drug Metab Dispos* 1997;25:133-9.
121. Patwardhan RV, Yarborough GW, Desmond PV, Johnson RF, Schenker S, Speeg KJ. Cimetidine spares the glucuronidation of lorazepam and oxazepam. *Gastroenterology* 1980;79:912-6.
122. Ghabrial H, Desmond PV, Watson KJ, Gijsbers AJ, Harman PJ, Breen KJ, et al. The effects of age and chronic liver disease on the elimination of temazepam. *Eur J Clin Pharmacol* 1986;30:93-7.
123. Health Canada. Canada's alcohol and other drugs survey. 1995;77:1-6.
124. Lemberger L. Tetrahydrocannabinol metabolism in man. *Drug Metab Dispos* 1972;1:461-8.
125. Lemberger L, Weiss JL, Watanabe AM, Galanter IM, Wyatt RJ, Cardon PV. Delta-9-tetrahydrocannabinol. Temporal correlation of the psychologic effects and blood levels after various routes of administration. *N Engl J Med* 1972;30:685-8.
126. Bornheim LM, Lasker JM, Raucy JL. Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol. *Drug Metab Dispos* 1992;20:241-6.
127. Watanabe K, Matsunaga T, Yamamoto I, Funae Y, Yoshimura H. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. *Biol Pharm Bull* 1995;18:1138-41.
128. Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS, et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. *AIDS* 2002;16:543-50.
129. McDowell JA, Chittick GE, Pilati-Stevens C, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. *Antimicrob Agents Chemother* 2000;44:1686-90.

130. Tanaka E, Misawa S. Pharmacokinetic interactions between acute alcohol ingestion and single doses of benzodiazepines, and tricyclic and tetracyclic antidepressants — an update. *J Clin Pharm Ther* 1998;23: 331-6.
131. Klotz U, Ammon E. Clinical and toxicological consequences of the inductive potential of ethanol. *Eur J Clin Pharmacol* 1998;54:7-12.
132. Kostrubsky VE, Strom SC, Wood SG, Wrighton SA, Sinclair PR, Sinclair JF. Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. *Arch Biochem Biophys* 1995;322:516-20.
133. Hsu A, Bertz R, Granneman GR. Assessing ritonavir dose effect on the pharmacokinetic parameters of protease inhibitors (abstract 3.3). Presented at: 2nd International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the Netherlands, April 2–4, 2001.
134. Degen O, Kurowski M, Van Lunzen J, Schewe CK, Stellbrink H. Amprenavir and ritonavir: intraindividual comparison of different doses and influence of concomitant NNRTI on steady-state pharmacokinetics in HIV-infected patients (abstract 739). Presented at: 8th Conference on Retroviruses and Opportunistic Infections, Chicago, February 4–8, 2001:267.

EXTRACTO

OBJETIVO: Resumir los datos que existen sobre las interacciones potenciales entre las drogas recreativas y aquellas comúnmente usadas en el manejo de pacientes con VIH.

FUENTES DE DATOS: Se obtuvo información por medio de una búsqueda en el banco de datos de MEDLINE (años 1966—agosto 2002) usando los términos MESH tales como “virus de inmunodeficiencia humana”, “interacciones”, “citocromo P450”. También se uso en la búsqueda nombres de medicamentos comúnmente prescritos en el manejo del VIH e infecciones oportunistas relacionadas y nombres de los medicamentos de recreación comúnmente usados. También se repaso extractos de conferencias nacionales e internacionales, artículos de repaso, textos y referencias de todos los artículos encontrados.

SELECCION DE ESTUDIOS Y EXTRACCIÓN DE DATOS: Literatura sobre interacciones farmacocinéticas fue considerada para inclusión. En la ausencia de datos específicos, la predicción de interacciones significativas clínicas potenciales fue basada en características farmacocinéticas y farmacodinámicas.

RESULTADOS: Todos los inhibidores de proteasa e inhibidores de la transcriptasa reversa no nucleósidos son sustratos y potentes inhibidores o inductores del sistema de encima citocromo P450. Muchas clases de drogas recreativas, incluyendo las benzodiazepinas, anfetaminas y opioides, también son metabolizados por el hígado y pueden interactuar potencialmente con los antirretrovirales. Frecuentemente no existen estudios de interacciones controlados, pero se ha observado interacciones clínicas significativas en un número de casos reportados. Se han reportado sobredosis secundarias entre drogas de “rave” como la MDMA y GHB e inhibidores de proteasa. Los inhibidores de proteasa, particularmente el ritonavir, también pueden inhibir el metabolismo de anfetaminas, ketamina, LSD, y PCP. Series de casos e estudios farmacocinéticos sugieren que la nevirapina y el efavirenz pueden inducir el metabolismo de metadona, lo cual puede resultar en síntomas de retiro de opioides. Una interacción similar puede existir entre metadona y los inhibidores de proteasa ritonavir y nelfinavir, aunque los datos de estas interacciones son menos consistentes. El metabolismo opiáceo se puede inhibir o inducir con el uso concomitante de inhibidores de proteasa y se debe monitorear estos pacientes para síntomas de toxicidad y/o pérdida de analgesia. No se debe de administrar los inhibidores de proteasa conjuntamente al midazolam y triazolam, ya que la combinación puede resultar en sedación prolongada.

CONCLUSIONES: Pueden ocurrir interacciones entre agentes comúnmente prescritos para pacientes con VIH y drogas recreativas, y estas

combinaciones pueden tener serias consecuencias clínicas. Los clínicos deben de tener un dialogo abierto con sus pacientes en cuanto a este tópico para así poder evitar comprometer la eficacia o aumentar el riesgo de toxicidad a estos medicamentos.

Carlos C da Camara

RÉSUMÉ

OBJECTIF: Rassembler toutes les données disponibles concernant les interactions médicamenteuses possibles entre les agents antirétroviraux fréquemment utilisés pour le traitement de l'infection par le VIH et les médicaments consommés à des fins “récréationnelles” ou drogues de rue.

REVUE DE LITTÉRATURE: L'information a été obtenue par une recherche effectuée dans la banque informatisée Medline (1966—août 2002) en employant les mots-clé suivants : virus de l'immunodéficience humaine, interactions médicamenteuses, cytochrome P-450, les noms des médicaments utilisés fréquemment pour le traitement de l'infection par le VIH ainsi que des infections opportunistes l'accompagnant et le nom des drogues de rue les plus souvent consommées. Les abrégés de conférences nationales ou internationales, les articles de revue, les livres de base ainsi que les articles cités dans la bibliographie des documents consultés ont aussi été analysés.

SÉLECTION DES ÉTUDES ET DE L'INFORMATION: Tous les articles sur les interactions de nature pharmacocinétique ont été inclus. L'information pertinente a été extraite et synthétisée pour faire l'objet de la discussion. En l'absence de données spécifiques, des prévisions d'interactions possibles cliniquement significatives ont été basées sur les propriétés pharmacocinétiques et pharmacodynamiques des médicaments.

RÉSULTATS: Tous les inhibiteurs de la protéase et les inhibiteurs non nucléosidiques de la transcriptase inverse sont des substrats et des inhibiteurs ou des inducteurs potentiels du système enzymatique du cytochrome P450. Plusieurs classes de drogues de rue, incluant les benzodiazépines, les amphétamines et les opiacés sont aussi métabolisées par le foie et peuvent possiblement interagir avec les agents antirétroviraux. Des données issues d'études contrôlées concernant les interactions médicamenteuses sont rarement disponibles mais des interactions cliniquement significatives ont été observées chez un bon nombre de patients. Des intoxications secondaires à la prise concomitante des médicaments “rave” 3,4-méthylènedioxyméthamphétamine (MDMA, ecstasy) et gamma hydroxybutyrate (GHB) avec les inhibiteurs de la protéase ont été rapportées. Les inhibiteurs de la protéase, particulièrement le ritonavir, peuvent aussi inhiber le métabolisme des amphétamines, de la kétamine, du LSD et du PCP. Des séries de cas et des études sur la pharmacocinétique suggèrent que la névirapine et l'efavirenz induisent le métabolisme de la méthadone et peuvent provoquer des symptômes de sevrage aux opiacés. Une interaction semblable peut exister entre la méthadone et les inhibiteurs de la protéase ritonavir et nelfinavir, mais les données sont moins concluantes. Le métabolisme des opiacés peut être inhibé ou induit par l'administration concomitante des inhibiteurs de la protéase et les patients devraient être suivi afin de détecter des signes de toxicité ou une perte d'efficacité analgésique. Les inhibiteurs de la protéase ne devraient pas être co-administrés avec le midazolam ou le triazolam car une sédation prolongée pourrait apparaître.

CONCLUSIONS: Des interactions médicamenteuses entre les agents antirétroviraux utilisés pour le traitement de l'infection par le VIH et les drogues de rue peuvent survenir et peuvent présenter des effets cliniques indésirables importants. Les cliniciens devraient encourager des discussions franches avec leurs patients sur ce sujet afin d'éviter de compromettre l'efficacité antirétrovirale des divers agents et d'augmenter le risque de toxicité.

Denyse Demers